Protocol Ledger

NCT06066125 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT06066125 sponsored by Akeso in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-31 Enrollment: 351 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06066125
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)351 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06066125
Protocol FieldVerified Registry Value
NCT IdentifierNCT06066125
Consolidated Lead SponsorAkeso
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment351 participants (ACTUAL)
Registered Start Date2023-03-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI